CHA News

No Surprises Act Rule Released, Requires Health Plans to Report Prescription Drug and Health Care Spending Data

For CEOs, CFOs, government relations executives, finance & reimbursement staff, legal counsel

This post has been archived and contains information that may be out of date.

On Nov. 17, the Departments of Health and Human Services, Labor, and Treasury (tri-agencies) released an interim final rule implementing provisions of the No Surprises Act.  

The rule requires health plans to report certain prescription drug and health care spending data to the tri-agencies. The prescription drug data will include information on rebates paid by manufacturers to plans, as well as the most frequently dispensed brand name drugs, costliest dispensed drugs, and drugs with the largest increase in year-over-year expenditures.

The data plans must submit on health spending will be broken down by hospital care, primary care, specialty care, prescription drugs, and other medical costs. Starting in 2023, the tri-agencies will use this data to issue public reports on prescription drug pricing trends and the impact of drug costs on premiums.